---
title: Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
date: '2024-06-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38899716/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240621182523&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: After nearly 10 years of follow-up, adjuvant therapy with
  dabrafenib plus trametinib was associated with better relapse-free survival and
  distant metastasis-free survival than placebo among patients with resected stage
  III melanoma. The analysis of overall survival showed that the risk of death was
  20% lower with combination therapy than with placebo, but the benefit was not significant.
  Among patients with melanoma with a BRAF V600E mutation, the results suggest that
  the risk ...'
disable_comments: true
---
CONCLUSIONS: After nearly 10 years of follow-up, adjuvant therapy with dabrafenib plus trametinib was associated with better relapse-free survival and distant metastasis-free survival than placebo among patients with resected stage III melanoma. The analysis of overall survival showed that the risk of death was 20% lower with combination therapy than with placebo, but the benefit was not significant. Among patients with melanoma with a BRAF V600E mutation, the results suggest that the risk ...